## Nobiletin

®

MedChemExpress

Cat. No.:	HY-N0155		
CAS No.:	478-01-3		0
Molecular Formula:	C <sub>21</sub> H <sub>22</sub> O <sub>8</sub>		° °
Molecular Weight:	402.39		
Target:	Autophagy; ROR;	Reactive Oxygen Species; Apoptosis	
Pathway:	Autophagy; Metak Immunology/Infla	olic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; mmation; NF-кB; Apoptosis	
Storage:	Powder -20°C	3 years	
	4°C	2 years	
	In solvent -80°C	1 year	
	-20°C	6 months	

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (124.26 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	2.4852 mL	12.4258 mL	24.8515 mL
		5 mM	0.4970 mL	2.4852 mL	4.9703 mL
		10 mM	0.2485 mL	1.2426 mL	2.4852 mL
	Please refer to the so	lubility information to select the app	propriate solvent.		
In Vivo	1. Add each solvent o Solubility: ≥ 2.5 m	one by one: 10% DMSO >> 90% (20 g/mL (6.21 mM); Clear solution	% SBE-β-CD in saline)		
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.17 mM); Clear solution				
	3. Add each solvent o Solubility: ≥ 2.08 n	one by one: 10% DMSO >> 90% cor ng/mL (5.17 mM); Clear solution	n oil		

Description	Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes and has anti-inflammation and anti-cancer properties, including anti-angiogenesis, anti-proliferation, anti-metastasis and induced apoptosis <sup>[1][2][3][4]</sup> .	
IC <sub>50</sub> & Target	Retinoid acid receptor-related orphan receptors (RORs) <sup>[1]</sup> ; reactive oxygen species (ROS) <sup>[1]</sup> ; apoptosis <sup>[2]</sup>	

Product Data Sheet

|--|

Nobiletin (0-100  $\mu$ M; 24 hours; U2OS and HOS cells) treatment progressively reduces protein expressions of MMP-2 and MMP-9. In U2OS and HOS cells, Nobiletin considerably reduces the phosphorylation of p-IKK $\alpha/\beta$  and p-I $\kappa$ B $\alpha$ , and protein expression of NF- $\kappa$ B in the cell nuclear fraction with the concomitant increase of the NF- $\kappa$ B expression in the cytosolic fraction. Nobiletin down-regulates the p-CREB and the SP-1 expressions in the nuclear fraction, whereas Nobiletin does not affect c-Jun and c-Fos expressions<sup>[1]</sup>.

Nobiletin (0-100  $\mu$ M; 24 hours; U2OS and HOS cells) treatment significantly reduces mRNA expressions of MMP-2 and MMP-9 dose-dependently in U2OS and HOS cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	U2OS and HOS cells
Concentration:	0 μΜ, 25 μΜ, 50 μΜ, 75 μΜ, 100 μΜ
Incubation Time:	24 hours
Result:	Progressively reduced protein expressions of MMP-2 and MMP-9. Considerably reduced the phosphorylation of p-IKK $\alpha/\beta$ and p-I $\kappa$ B $\alpha$ , and protein expression of NF- $\kappa$ B in the cell nuclear fraction with the concomitant increase of the NF- $\kappa$ B expression in the cytosolic fraction. Down-regulated the p-CREB and the SP-1 expressions in the nuclear fraction in U2OS and HOS cells.
RT-PCR <sup>[1]</sup>	

Cell Line:	U2OS and HOS cells
Concentration:	0 μΜ, 25 μΜ, 50 μΜ, 75 μΜ, 100 μΜ
Incubation Time:	24 hours
Result:	Significantly reduced mRNA expressions of MMP-2 and MMP-9 dose-dependently in U2OS and HOS cells.

In Vivo

Nobiletin (0.1% of regular diet; oral administration; daily; for 20 weeks; male C57BL/6 mice) treatment restores glucose homeostasis and promots energy expenditure and circadian activity in aged mice<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	20- to 22-month-old male C57BL/6 mice <sup>[2]</sup>
Dosage:	0.1% of regular diet
Administration:	Oral administration; daily; for 20 weeks
Result:	Fully restored glucose tolerance in aged mice, and increased basal body temperature and cold tolerance in aged mice. Led to a twofold increase in distance run/day on voluntary wheels compared with aged regular diet-fed mice during the active phase.

## CUSTOMER VALIDATION

- Acta Pharm Sin B. 2021 Jan;11(1):143-155.
- Int J Biol Sci. 2022 Sep 11;18(15):5698-5712.
- Food Funct. 2023 Jul 19.

- J Agric Food Chem. 2022 Feb 9;70(5):1536-1546.
- Nutrients. 2023 May 8, 15(9), 2228.

See more customer validations on <u>www.MedChemExpress.com</u>

## REFERENCES

[1]. Cheng HL, et al. Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression. Oncotarget. 2016 Jun 7;7(23):35208-23.

[2]. Nohara K, et al. Nobiletin fortifies mitochondrial respiration in skeletal muscle to promote healthy aging against metabolic challenge. Nat Commun. 2019 Aug 28;10(1):3923.

[3]. He B, et al. The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell Metab. 2016 Apr 12;23(4):610-21.

[4]. Takito J, et al. Nerve growth factor enhances the CRE-dependent transcriptional activity activated by nobiletin in PC12 cells. Can J Physiol Pharmacol. 2016 Jul;94(7):728-33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA